Business Context and Reporting Period
This Form 8-K is a current report filed by Rein Therapeutics, Inc. (RNTX) on February 16, 2026. The filing discloses a corporate governance event regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
On February 16, 2026, Manuel C. Alves Aivado, M.D., Ph.D., resigned as a member of the Board of Directors, effective immediately. The Company stated that the resignation was not the result of any disagreement with the Company regarding its operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance. No specific risks or contingencies were disclosed in this report other than the immediate reduction in Board membership.
Investor Verification Checklist
- Verify the composition of the Board of Directors following Dr. Aivado's resignation.
- Confirm whether the Company intends to appoint a replacement director in the near term.
- Review recent 10-K or 10-Q filings for the most current financial position, as this 8-K contains no financial data.